
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Miami - Dermatologists who ask the right questions when they see children with cutaneous conditions might discover that academic, emotional, or social problems are at the root of some of these skin disorders.